Benefits
Triglyceride reduction
The most well-established omega-3 benefit. EPA+DHA at 2-4 g/day consistently lowers blood triglycerides by 20-30% in people with elevated baseline levels. Effect is dose-dependent and robust across populations. This indication is solid enough that the FDA has approved prescription omega-3 products (Lovaza, Vascepa, Epanova) specifically for severe hypertriglyceridemia, and the American Heart Association endorses 4 g/day for that condition.
Cardiovascular events in high-risk patients
In statin-treated patients with elevated triglycerides, high-dose purified EPA (icosapent ethyl, 4 g/day) reduces major cardiovascular events by about 25%. Formulation matters: EPA+DHA mixtures haven't replicated this benefit in similar populations. Both EPA-only and EPA+DHA modestly increase atrial fibrillation risk. Most relevant for high-risk cardiac patients under physician supervision; the cardiovascular case for routine supplementation in healthy adults is weaker.
Depression — EPA-rich formulas as antidepressant adjunct
Omega-3 reduces depressive symptoms when added to standard antidepressant therapy in major depression. EPA-rich formulations (≥60% EPA) work meaningfully better than DHA-rich or balanced products — most users buying generic 'fish oil' for mood get a suboptimal ratio. International nutritional psychiatry guidelines recommend 1-2 g EPA per day as antidepressant adjunct. Effect is smaller in dementia and cardiovascular-comorbid populations.
Liver health — NAFLD and hepatic fat reduction
Omega-3 supplementation at 2-4 g/day for 12+ weeks reduces liver enzymes (ALT drops ~9 U/L, AST also down) and decreases hepatic fat content in non-alcoholic fatty liver disease. Mechanism: reduced fat production in the liver (SREBP-1c suppression), increased fat burning (PPAR-α activation), and reduced inflammatory signaling. Reasonable adjunct in NAFLD/MASLD management alongside dietary changes.
Rheumatoid arthritis — joint pain and stiffness
At 2.7+ g/day combined EPA+DHA, omega-3 reduces joint tenderness, stiffness, and NSAID use in rheumatoid arthritis. Effect is meaningful enough to register on disease activity scores — but it's not a replacement for DMARDs. Mechanism: omega-3 metabolites (resolvins, protectins, maresins) actively help resolve inflammation rather than just blocking it like NSAIDs do. Reasonable adjunct to RA treatment under rheumatologist guidance.
Pregnancy — preterm birth risk reduction
DHA supplementation during pregnancy (800 mg/day) reduces the risk of early preterm birth (before 34 weeks). DHA also supports fetal brain and retinal development. ACOG recommends a 200 mg/day DHA minimum during pregnancy as the floor — supplementation above this is reasonable for women with low fish intake. Postpartum depression evidence is mixed and less reliable than the preterm birth signal.
Cognitive decline — observational positive, supplements null
Higher omega-3 intake is associated with lower dementia risk in observational studies. But the gold-standard randomized trial of 1 g/day EPA+DHA over 5 years found NO cognitive benefit. Most likely explanation: DHA matters during development and in deficient adults, but adding more to already-adequate intake doesn't help. Eat fish for cognitive health if your diet is low; routine fish oil supplementation as a 'brain health' strategy isn't well-supported by trial data.
Eye health — dry eye disease, mixed AMD evidence
For dry eye disease, omega-3 at 1-2 g/day provides meaningful symptom relief and is endorsed in TFOS DEWS II clinical guidelines. For age-related macular degeneration, the evidence is contradictory: the gold-standard supplementation trial was null, but genetic predisposition to higher omega-3 levels is associated with lower AMD risk in large population data. Reasonable for dry eye; not validated for AMD prevention via supplementation.
Skin — atopic dermatitis, psoriasis, and acne
Omega-3 reduces severity of atopic dermatitis, psoriasis, and acne — most clearly in people with low baseline omega-3 intake. Mechanism: shifts inflammatory balance away from leukotriene-mediated skin inflammation toward pro-resolving mediators. Evidence is preliminary compared to the cardiovascular and mood indications. Reasonable supportive strategy for inflammatory skin conditions, not a replacement for dermatologic care.
Mechanism of action
Cardiovascular Protection
Omega-3 fatty acids (EPA and DHA) reduce triglycerides by inhibiting hepatic VLDL synthesis and enhance endothelial function by increasing nitric oxide production, lowering blood pressure and improving vascular health.
Anti-Inflammatory Effects
Omega-3s are metabolized into resolvins and protectins, which inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-6) and reduce inflammation via pathways like NF-kB suppression.
Neuronal Membrane Stabilization
DHA, a major component of neuronal membranes, maintains membrane fluidity and supports synaptic function, enhancing neuroplasticity and cognitive performance.
Neurotransmitter Modulation
Omega-3s increase serotonin and dopamine signaling by altering receptor function and reducing inflammation, potentially improving mood and reducing depression symptoms.
Retinal Function Support
DHA is incorporated into retinal cell membranes, supporting photoreceptor function and protecting against oxidative stress, which benefits eye health.
Joint Health Improvement
Omega-3s reduce prostaglandin E2 production by inhibiting COX-2 enzymes, decreasing inflammation and pain in joints, particularly in rheumatoid arthritis.
Skin Barrier Enhancement
Omega-3s integrate into skin cell membranes, improving barrier function and reducing inflammation, which helps alleviate symptoms of skin conditions like eczema.
Fetal Development Support
DHA supports fetal brain and retinal development by providing essential structural lipids and promoting neurogenesis and synaptogenesis during pregnancy.
Clinical trials
2014 randomized, double-blind, placebo-controlled trial (NCT00345176), part of AREDS2, examining omega-3 (DHA + EPA, 1 g/day) and lutein/zeaxanthin effects on cognitive function in 4,203 older adults. (AREDS2 Research, JAMA)
4,203 older adults. 5-year follow-up.
Primary endpoint negative: omega-3 did not improve cognitive function vs placebo. Important rigorous trial that contradicted earlier observational hopes for omega-3 cognitive protection.
2019 randomized, double-blind, placebo-controlled trial (NCT01492361) in 8,179 patients with established CV disease or T2DM + CV risk factors and elevated triglycerides on statins receiving icosapent ethyl (Vascepa, 4 g/day pure EPA) vs mineral oil placebo. (NEJM)
8,179 high-risk CV patients on statins.
Icosapent ethyl reduced primary CV endpoint by 25% (composite of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, unstable angina) vs placebo. Critical context: this is a pharmaceutical — purified EPA (4 g/day = vastly higher than typical fish oil dose). Vascepa® FDA-approved 2019. Controversy: mineral oil placebo may have been pro-inflammatory, potentially inflating effect; STRENGTH-CHF and strength trials of mixed EPA/DHA at similar doses were negative. Suggests EPA-only at high pharmaceutical doses may be the active intervention.
2020 randomized, double-blind, placebo-controlled trial (NCT02104817) in 13,078 patients with high CV risk receiving omega-3 carboxylic acids (Epanova, 4 g/day mixed EPA + DHA) vs corn oil placebo. (JAMA)
13,078 high CV risk patients on statins.
Primary endpoint negative: omega-3 did not reduce CV events vs placebo. Trial stopped early for futility. Important finding: contradicts REDUCE-IT, suggesting either EPA-only superiority or REDUCE-IT mineral oil placebo issue. Modern view: supplemental fish oil for general CV prevention — evidence is much weaker than typical marketing.
2018 randomized, double-blind, placebo-controlled trial (NCT02336074) in 1,100 pregnant women at high risk of preterm birth receiving omega-3 vs placebo.
1,100 high-risk pregnant women.
Modest signal for preterm birth reduction. Note: ORIP trial (NEJM, n=5,544) — larger definitive Australian trial — was negative for term birth and maternal outcomes overall. Preterm birth prevention with omega-3 has mixed evidence; should be discussed with obstetric care provider.
2015 randomized, double-blind, placebo-controlled trial in 196 adults with MDD receiving EPA, DHA, or placebo for 8 weeks. (Transl Psychiatry — or related)
196 MDD patients.
Modest depression score improvement with EPA-rich preparations vs placebo, particularly in those with elevated inflammatory markers. Note: pooled analyses suggest EPA-PREDOMINANT formulations (≥60% EPA, ≥1 g EPA/day) are more effective than DHA-predominant for depression. Should be considered adjunctive — not replacement for antidepressants in moderate-severe MDD.
2019 randomized, double-blind, placebo-controlled trial in 144 youths aged 6-18 with ADHD. (Transl Psychiatry)
144 youths with ADHD.
EPA particularly modestly improved attention scores vs placebo, with greater benefit in those with low baseline omega-3 status. Note: ADHD treatment requires comprehensive evaluation; omega-3 has modest adjunctive role; stimulants and behavioral therapy remain first-line.
2006 randomized, double-blind, placebo-controlled trial (OmegAD) in 204 patients with mild-to-moderate AD receiving DHA-rich omega-3 vs placebo. (Freund-, Arch Neurol)
204 mild-moderate AD patients.
Primary endpoint negative overall. Subgroup with very mild AD showed cognitive stabilization. Subsequent larger MIDAS, alpha-Omega trials also weak. Modern AD landscape includes lecanemab/donanemab; omega-3 has no established AD treatment role.
2017 clinical trial in 139 patients with active RA receiving omega-3 vs placebo. (Various RA omega-3 trials.)
139 RA patients.
Modest reductions in joint pain, morning stiffness, and NSAID requirement vs placebo. Established adjunctive role in RA; mechanism via anti-inflammatory eicosanoid pathway. Modern RA care uses biologics (anti-TNF, JAK inhibitors); omega-3 adjunctive.
2011 randomized, double-blind, placebo-controlled trial in 27 children aged 3-8 with ASD receiving omega-3 vs placebo.
27 children with ASD (very small).
Modest signals on behavioral measures. Critical caveat: very small trial; subsequent larger trials and Cochrane reviews have not shown definitive ASD benefits from omega-3. Do not extrapolate to definitive ASD treatment.
2012 randomized, double-blind, placebo-controlled trial (NCT00970489, OPERA) in 1,516 patients undergoing cardiac surgery receiving omega-3 vs placebo. (JAMA)
1,516 cardiac surgery patients.
Primary endpoint negative: omega-3 did not reduce postoperative AFib vs placebo. Important rigorous negative trial.
Evidence review and pooled analysis of 15 clinical trials and cohort studies (-) evaluating omega-3 PUFAs in NAFLD. (2024)
Pooled across 15 NAFLD studies.
Omega-3 modestly reduced ALT (~-2.12) and AST (~-1.50) vs placebo. Histologic improvements limited. Note: NAFLD landscape transformed by GLP-1 agonists and resmetirom; omega-3 adjunctive at most.